Although ICB has significant tumor suppressor efficacy in the tumor treatments, only a few patients benefit from it . A critical reason for this phenomenon is that the insufficient infiltration of T cells into tumors causing poor immune response . In recent years, novel approaches to boost the antitumor immune response, such as photothermal therapy (PPT), photodynamic therapy (PDT), sonodynamic therapy (SDT) and etc., have recently gained increased interest. SDT, as a non-invasive therapy, hold the advantages of strong tissue penetration and little damage to normal tissues. Sonodynamic therapy can induce highly toxic reactive oxygen species (ROS) in tumor to kill tumor cells in the presence of sonosensitizers and low-intensity ultrasoundinduced sonosensitizers . SDT complements the lack of patient response to immunotherapy by increasing the infiltration of CD8 + T cells . Clinical animal experiments have shown that tumor cell fragments produced by SDT can be considered as tumor antigens to trigger host anti-tumor immune response . Therefore, we envision that integrating ICB immunotherapy and SDT may provide an advanced nanoplatform for effective tumor treatment. Combination of checkpoint inhibition through anti-PD-L1 antibody and SDT was also recently reported for treatment of metastatic breast tumor and showed exciting effect .